Docetaxel, Estramustine, and Exisulind in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00052845|
Recruitment Status : Completed
First Posted : January 27, 2003
Last Update Posted : July 1, 2016
RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Estramustine may fight prostate cancer by reducing the production of androgens. Exisulind may stop the growth of prostate cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining these therapies may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of combining estramustine with exisulind and docetaxel in treating patients who have metastatic prostate cancer that has not responded to hormone therapy.
|Condition or disease||Intervention/treatment||Phase|
|Prostate Cancer||Drug: docetaxel Drug: estramustine phosphate sodium Drug: exisulind||Phase 2|
- Determine the time to objective and biochemical progression and response proportion (objective and post-therapy changes in PSA) in patients with hormone refractory metastatic prostate cancer treated with docetaxel, estramustine, and exisulind.
- Determine the toxic effects of this regimen in these patients.
- Determine the overall survival of patients treated with this regimen.
OUTLINE: Patients receive oral estramustine 3 times daily on days 1-5, docetaxel IV over 1 hour on day 2, and oral exisulind twice daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Patients are followed every 3 months for 2 years.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||80 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase II Study Of Estramustine, Docetaxel, And Exisulind (IND #64733) In Men With Hormone Refractory Prostate Cancer|
|Study Start Date :||November 2002|
|Primary Completion Date :||January 2006|
|Study Completion Date :||April 2009|
Experimental: Combined chemotherapy
combination of 3 chemotherapy agents for hormone refractory prostate cancer
70 mg/sq m IV infusion over 1 hour Day 2 of ea cycleDrug: estramustine phosphate sodium
280 mg PO tid Days 1-5 of ea cycleDrug: exisulind
Two 125 mg capsules PO bid Days 1-21 of ea cycle
- Time to progression [ Time Frame: 24 months from study entry ]
- Toxicity [ Time Frame: treatment up to 3 mon post treatment ]
- Changes in PSA [ Time Frame: During treatment then q 3 mon until ds progression ]
- Overall Survival [ Time Frame: 24 months from study entry ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00052845
Show 80 Study Locations
|Study Chair:||Nancy Dawson, MD||University of Maryland Greenbaum Cancer Center|